KPTI 241220 2.50C (KPTI241220C2500) Stock Options, News & Quotes

US OptionsDetailed Quotes

KPTI241220C2500

Watchlist

0.10
0.000.00%

15min DelayClose Nov 22 15:58 ET

0.00High0.00Low

Intraday

5D
Daily

News

Express News | Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
ReutersNov 20 16:05 ET
Press Release: Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
Dow JonesNov 20 16:05 ET
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
Karyopharm TherapeuticsNov 18 00:00 ET
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Yahoo FinanceNov 8 05:42 ET
Cautious Hold Rating on Karyopharm Therapeutics Amid Incremental Revenue Growth and Pending Clinical Trial Outcomes
TipRanksNov 8 02:29 ET · Ratings
Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Raises Target Price to $5
Moomoo NewsNov 6 08:37 ET · Ratings

Comments

Furqan786

Nov 7 07:32

$Karyopharm Therapeutics (KPTI.US)$ better buy now, price will go up to 2usd

Furqan786

Oct 31 09:32

$Karyopharm Therapeutics (KPTI.US)$ buy now lots of good news

Jaguar8

Oct 31 06:39

NEWS

$Karyopharm Therapeutics (KPTI.US)$
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics (Nasdaq: KPTI)announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025.
Phase 1 trial data showed pr...

Trytosaveabit

Oct 31 06:35

Update

$Karyopharm Therapeutics (KPTI.US)$ Reuters· 5 mins ago
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 Sentry Trial in Myelofibrosis

QMengColdJoke

Aug 29 15:40

Yeah CFO is gone, just hire someone on street!

$Karyopharm Therapeutics (KPTI.US)$ This dude was hired when stock price was 10 dollar. Now we are screwed. looks like a let resign. He’s good controller but probably a really bad CFO.